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Abstract Retinoic acid, the active form of the nutrient
vitamin A, regulates several facets of neuronal plasticity in
the hippocampus, including neurogenesis and synaptic
strength, acting via speciﬁc retinoic acid receptors (RARs).
Essential for conversion of vitamin A to retinoic acid is the
enzyme retinaldehyde dehydrogenase (RALDH) and in the
rodent hippocampus this is only present in the adjacent
meninges where it must act as a locally released paracrine
hormone. Little is known though about the expression of
RALDHs and RARs in the human hippocampus. This study
conﬁrms that RALDH levels are very low in mouse neu-
rons but, surprisingly, strong expression of RALDH protein
is detected by immunohistochemistry in hippocampal
neurons. The receptors RARa, b and c were also detected,
each receptor exhibiting differing subcellular locations
implying their potential regulation of both transcription and
non-genomic actions. These results imply an essential
function of retinoic acid in the human hippocampus likely
to include regulation of neuronal plasticity.
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Introduction
The nuclear receptor superfamily of transcriptional regu-
lators includes a number of receptors for lipid hormones
including oestrogen, androgen, thyroid hormone and the
corticosteroids. Several other receptors in this family are
for lipid hormone-like ligands; this includes vitamin D,
which through its activation and release by the kidney
functions as a paracrine hormone (Bell 1985) while vitamin
A through its active metabolite retinoic acid (RA) functions
as a locally released paracrine or autocrine hormone, acting
via retinoic acid receptors (RARs). The retinoid X recep-
tors (RXRs) can heterodimerise with vitamin D receptor
and RARs as well as the thyroid hormone receptors
(Shaffer and Gewirth 2004; Glass 1996). Vitamin A is
stored in the body as retinyl esters which are hydrolysed
and released as retinol to maintain a constant 1 lM con-
centration of retinol in the plasma, bound to retinol-binding
protein (Blomhoff 1994). Cells actively take up retinol and
oxidise this to RA which diffuses locally to activate nearby
cells (Blomhoff 1994).
This system is essential for development of many organ
systems in the embryo (Sporn et al. 1994) including the
CNS (McCaffery et al. 2003), but its importance for the
postnatal brain has only been relatively recently recogni-
sed. The hippocampus had been an area of particular focus
in this research (McCaffery et al. 2006) where RA
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developing brain, modulating neuronal plasticity. Hippo-
campal function in learning and memory is dependent on
plastic changes in synaptic strength, numbers of synapses
and neurons, all of which can be modiﬁed and in which
RA plays a role (McCaffery et al. 2006). The number of
granule neurons in the dentate gyrus is modiﬁed through
regulated neurogenesis (Alvarez-Buylla and Lim 2004)
and this can be controlled by RA in a biphasic fashion
with both a deﬁciency (Jacobs et al. 2006) and excess
(Crandall et al. 2004) leading to diminished neurogenesis
and decline in performance in a radial maze (Crandall
et al. 2004). When rats are deﬁcient in vitamin A, mod-
iﬁcation of synaptic strength through long-term potentia-
tion is reduced together with their ability to perform in a
radial maze (Misner et al. 2001; Cocco et al. 2002).
Further, when the RARs are functionally removed by
mutation in mice then this results in deﬁcits in both long-
term potentiation and long-term depression as well as the
expected deﬁcits in performance in hippocampal-depen-
dent learning and memory tasks (Chiang et al. 1998).
More recently it has been shown that synaptic scaling,
necessary for overall homeostatic regulation of a neuron’s
synapses requires RA to maintain this stability, surpris-
ingly not through RARs regulation of transcription but
rather though modiﬁcation of translation (Aoto et al.
2008; Poon and Chen 2008).
The RARs that mediate these events are distributed
throughout the mammalian brain as has been shown
extensively in the mouse and rat (Ruberte et al. 1993;
Zetterstrom et al. 1994, 1999; Krezel et al. 1999) and in
limited studies in the human (Rioux and Arnold 2005).
Also essential are the enzymes that synthesise RA from
retinol, performing this oxidation in two steps, the ﬁrst step
catalysed by ubiquitous retinol dehydrogenases, the ﬁnal
step by tissue speciﬁc retinaldehyde dehydrogenases
(RALDHs) (Mey and McCaffery 2004). Both steps are
essential, but in the rodent brain there is reported to be only
localised RALDH expression in certain cortical neurons as
well as the meninges surrounding the brain (Wagner et al.
2002; Luo et al. 2009). Although cultured neurons from the
hippocampus express the RALDHs (Rioux and Arnold
2005), there is little expression of these enzymes in vivo
and it is hypothesised that RA is derived from the meninges
by diffusion (Sakai et al. 2004). RA levels, at least in the
mouse hippocampus, must be low and the RA-regulated
hippocampal events described in the mouse may require
only very low levels of this paracrine hormone. The situ-
ation in the human hippocampus, however, has been
unexplored. This study conﬁrms that RALDH levels are
very low in mouse neurons but, to the contrary, qPCR
detects high levels of RALDH transcript in the human
hippocampus and corresponding strong expression of
RALDH protein in hippocampal neurons. This implies an
essential function of RA in the human hippocampus and,
from its described roles in the rodent hippocampus of
regulation of neuronal plasticity, this is potentially its role
in the human.
Methods
Preparation of tissues
The present study was approved by the Ethics Committee
of Universidade Metropolitana de Santos, SP, Brazil, and
by the Brazilian Health Research Committee on April
4th 2011, under the number CONEP 16168, documents
registered under the number 25000.169694/2010-18. Cau-
dal human hippocampi from six male individuals aged
55 years or less, who did not present any neurological or
psychiatric disease, were collected during necropsy pro-
cedures. Brains from individuals whose death was related
to head trauma, and extensive infection, toxic, anoxic or
metabolic injuries were excluded from this study. Samples
from the hippocampus, measuring typically 0.5 cm
3, were
ﬁxed in 10% buffered (NaH2PO4 and Na2HPO4) formalin
within 24 h from death and placed in parafﬁn blocks within
the following 24 h. Other samples from the same areas
were collected in RNAlater RNA Stabilization Reagent
(Qiagen, Venlo, The Netherlands) and stored at 4C for
qPCR or were freshly frozen for western blot analysis.
Mouse tissues were from adult male C57Bl6 mice aged
3 months (n = 3) bred from an in-house colony that were
kept on a 12L:12D light cycle. These animals were per-
fusion ﬁxed using 4% paraformaldehyde. All animal pro-
cedures were carried out in accordance with Home Ofﬁce
regulations and local ethics committee guidelines.
Western blotting
Human hippocampal protein was extracted in 0.01 M
phosphate buffer containing a protease inhibitor cocktail
(Sigma) using mechanical homogenisation and three
freeze–thaw cycles. Homogenates were centrifuged 10 min
at 12,000 rpm at 4C. Total protein levels in each sample
were quantiﬁed by the BCA assay (Pierce) and loaded onto
a 12% SDS-PAGE mini-gel, 50 lg total protein per lane.
After separation the proteins were transferred onto a
Hybond
TM-ECL nitrocellulose membrane (GE Healthcare)
using a Mini Trans-Blot Cell (Bio-Rad) and loading was
checked with Ponceau-S (Sigma). Membranes were probed
with the primary antibodies that were to be used for
immunohistochemistry of the RALDH enzymes; rabbit
anti-RALDH1 (Abcam 1:3,000), rabbit anti-RALDH2
(1:10,000) or rabbit anti-RALDH3 (1:10,000) overnight.
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123Staining was detected using a secondary HRP anti-rabbit
antibody (Sigma 1:5,000) and enhanced chemilumines-
cence (Millipore) incubated for 5 min followed by expo-
sure to X-ray ﬁlm (Thermo Fisher Scientiﬁc).
Immunohistochemistry
The samples were sectioned at 7 lm, onto A380-bond
slides (Electron Microscopy Sciences, Hatﬁeld PA 19440,
USA) and dried overnight at 37C. Parafﬁn was removed
from tissue samples with xylene and was rehydrated
through decreasing ethanol concentrations (100, 95, 80
and 70%). Antigen retrieval was achieved by microwa-
ving samples for 10 min in sodium citrate buffer, pH 6.0.
Samples were allowed to cool on the bench for 20 min
and were then washed in 1 9 PBS pH 7.4, containing 1%
Tween 20 (Sigma) and 1% pooled human serum (Bio-
Sera) (from now on referred as the PBS solution). From
this stage, immunohistochemistry was then carried out
with two different procedures depending on the staining
method.
Immunohistoperoxidase detection
The samples were incubated with 3% H2O2 in methanol for
10 min to block endogenous peroxidases and subsequently
washed with 1 9 PBS. Avidin–Biotin (Vector Labs)
blocking was performed to reduce non-speciﬁc binding.
Primary antibodies used were rabbit anti-RALDH1 (1:300,
Abcam), rabbit anti-RALDH2 [1:2,000, (Berggren et al.
1999)], rabbit anti-RALDH3 [1:3,000, (Wagner et al.
2002)], rabbit anti-RARa (1:300 Santa Cruz), rabbit anti-
RARb (1:300 Santa Cruz Biotechnology) and rabbit anti-
RARc (1:300 Santa Cruz Biotechnology). RALDH1 was
raised against a rat peptide and has been shown to react
with multiple tissues including human according to the
manufacturer’s description. RALDH2 and 3 were raised
against whole protein and the RALDH2 antibody has been
shown to recognise the human protein (Spiegl et al. 2008).
All the RAR antibodies are raised against human epitopes
and react with human tissue (Meng et al. 2011; Lu et al.
2005; Alique et al. 2007). After washing with 1 9 PBS, the
tissue was incubated with biotinylated secondary antibod-
ies (Sigma) for 1 h at room temperature. Subsequently, the
slides were washed with the PBS solution and incubated
for 1 h with Vecstatin ABC Elite (Vector Labs). After
further washing, the sections were exposed to 0.05% 3,30-
diaminobenzidine (Sigma) diluted 0.1% in PBS, to visu-
alise antibody staining. Nuclei staining was carried out
with haematoxylin staining, and tissue was dehydrated
through sequential ethanol concentrations followed by
xylene before mounting with DPX (Sigma).
Immunoﬂuorescent detection
Samples were incubated for 1 h, at room temperature, with
blocking solution (1 9 PBS pH 7.4 containing 0.3%
Tween 20, 5% normal goat serum, 5% bovine serum
albumin and 5% pooled human serum (Makitie et al. 2010)
tissue was incubated with the primary antibody diluted in
blocking solution and incubated overnight at 4C. Primary
antibodies and incubation procedures were the same as
described above. The primary antibody used in double-
labelling experiments to identify neurons was chicken anti-
MAP2 (1:500 Millipore).
After incubation, the slides were washed in the PBS
solution. The tissue was then incubated with the secondary
ﬂuorescent antibody [anti-rabbit 1:300 (Alexa Fluor,
Invitrogen) or anti-chicken 1:400 (DyLights, Stratech)]
diluted in the PBS solution, for 1 h, at room temperature.
Slides were washed in the PBS solution and incubated for
1 min with 10% Sudan Black (Acros Organics) made up
in 70% isopropyl alcohol to reduce auto-ﬂuorescence
(Schnell et al. 1999; Neumann and Gabel 2002). The slides
were then thoroughly washed in distilled water and
mounted with mounting medium containing 1,4-diazabi-
cyclo[2.2.2]octane (DABCO, Sigma) and bisbenzimide
(Sigma).
Quantitative PCR
TotalRNAwasextractedfromhippocampalsamplesusinga
RNeasy mini kit (Qiagen) with on column DNase treatment
(Qiagen). RNA was quantiﬁed using a Nanodrop spectro-
photometer (Thermo Scientiﬁc). cDNA was synthesised
using High Capacity RNA to cDNA Master Mix (Applied
Biosystems). qPCR analysis was performed using SensiMix
SYBR(Bioline)toassessthepresenceorabsenceofRALDH
and RAR gene expression in human (n = 3) samples.
Primers were designed for human analysis using human
RNAsequencesobtainedfromtheNCBIgenedatabase.The
primer sequences were as follows: RALDH1 (F: CAAGG
CAGTGAAGGCCGCAAGA, R: ATTGACTCCATTGTC
GCCAGCAGC), RALDH2 (F: CACTGAGCAGGGTC
CCCAGATTGA, R: AACCCCTTTCGGCCCAGTCCT),
RALDH3 (F: CGCAACCTGGAGGTCAAGTTCACC, R:
AGCCTTGTCCACGTCGGGCTTA), RARa (F: GAGGG
CTGTAAGGGCTTCTTCCG, R: TGAGCTCGCCCACCT
CAGGC), RARb (F: GCTTAATCTGTGGAGACCGCC
AGG, R: TGTGAGGCTTGCTGGGTCGT), RARc (F:
GGGGCATCAGCACTAAGGGAGCT, R: AGGCATTGG
GGTGGGGACCA) and GAPDH (F: TCTTTTGCGTCG
CCAGCCGA, R: AGTTAAAAGCAGCCCTGGTGAC
CA) was used as an internal control standard for all human
samples. Standard curves and blank controls were run for all
genes.SampleswererunonaLightCycler
480(Roche)and
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SW1.5software.Analysiswas
performed using relative quantiﬁcation and the Roche’s
E-method of quantiﬁcation which uses standard curve
derived efﬁciencies.
Cell counting
Photographs of slides were taken using a Nikon Eclipse
E400 microscope and images captured with a QICAM
Fast 1394 (QImaging) camera and analysed by Image J
cell counter plugin (Image Processing and Analysis in
JAVA; public domain, developed at the National Insti-
tutes of Health; NIH, USA). The total number of cells
was determined by counting of cell nuclei ﬂuorescently
labelled with bisbenzamide (blue) while the number of
immunolabelled cells was determined by counting of
cells ﬂuorescently labelled with either Alexa Fluor 546
(red, used for RAR or RALDH) or Alexa Fluor 488
(green, used for MAP2)-labelled secondary antibody.
For each antibody of interest 100 cells, either nuclear
stained (all cells) or MAP2 stained (neurons only) were
counted and of these the number of cells positive for the
RAR or RALDH antibodies was counted. For each
antibody 6 individual samples were quantiﬁed in 3 dif-
ferent sections per individual and between 3 and 5 ﬁelds
of view were counted. Average values of the counts
were taken and standard error of the mean shown. Data
were analysed using One-way ANOVA with Tukey
post-hoc testing.
Results
Expression of retinoic acid synthetic enzymes
in the mouse and human dentate gyrus
The RALDH enzymes are responsible for the ﬁnal oxida-
tive step to synthesise RA from vitamin A. Antibodies for
these proteins have been extensively used in rodent studies;
however, limited information is available as to their spec-
iﬁcity in humans. Western blotting of human hippocampus
showed that all three antibodies directed against the
RALDH proteins detected proteins of the appropriate
molecular weight (Fig. 1a); single bands were detected for
RALDH1 (54 kDa) and RALDH3 (56 kDa), whereas two
bands were evident for RALDH2 (55 and 36 kDa) as seen
for rodent tissue and the smaller protein may represent a
proteolytic fragment of the larger. In the mouse hippo-
campus these enzymes cannot be detected in neurons by
immunohistochemistry (Wagner et al. 2002), nor their
transcripts by in situ hybridization (Allen Brain Atlas
http://www.brain-map.org/) and the primary source for the
hippocampus is likely the meninges (Sakai et al. 2004).
This low expression is conﬁrmed here with DAB immu-
nohistochemistry in which the mouse hippocampus is
negative for RALDH3 and RALDH1 and 2 are only present
in the meninges (Fig. 1b–d). Using the same immunohis-
tochemical technique however, the human hippocampus
contrasted markedly with all three RALDH proteins
expressed in a proportion of cells in the dentate gyrus of the
Fig. 1 Prevalence of RALDH proteins in the mouse and human
hippocampus. The speciﬁcity of the RALDH antibodies to their
respective proteins in the human hippocampus was veriﬁed with
western blotting, identifying RALDH1 (54 kDa), RALDH2 (55 kDa)
and RALDH3 (56 kDa) (a). 3,30-diaminobenzidine (DAB) immuno-
histochemistry was used to determine differing expression patterns for
the RALDH protein in the mouse and human hippocampus. The
mouse hippocampus including the dentate gyrus (DG) showed no
expression of any of the RALDHs (b–d), but RALDH1 and RALDH2
were expressed in the underlying meninges (indicated by arrows). In
contrast the human hippocampus expressed all three RALDH
enzymes in cells of the dentate gyrus (e–g). Scale bars b–d 50 lm,
e–g 40 lm
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capacity of these neurons to synthesise RA.
Immunoﬂuorescent detection of retinoic acid synthetic
enzymes and receptors in the human dentate gyrus
To conﬁrm that the intense immunolabelling of RALDHs
in the dentate gyrus was not the result of non-speciﬁc
immunoperoxidase labelling, an immunoﬂuorescent tech-
nique was employed based on that of Makitie et al. (2010)
providing very sensitive and speciﬁc staining while effec-
tively quenching autoﬂuorescence. This was performed
with hippocampi from six adult individuals of age less than
55 years and representative images are shown of RALDH1
(Fig. 2a), RALDH2 (Fig. 2b) and RALDH3 (Fig. 2c),
demonstrating immunolabelling in cells of the dentate
gyrus. Double labelling with the neuronal marker MAP2
demonstrated that the RALDHs are present in neurons,
shown for RALDH1 expressed predominantly in its typical
cytoplasmic location (Fig. 2d).
The importance of RA signalling in the hippocampus
has been implied in the rodent from RA receptor expres-
sion [reviewed (McCaffery et al. 2006)] but very few
studies have explored receptor expression in the human.
All three RARs, a, b and c (Fig. 2e–g) were present in the
human dentate gyrus. Double labelling with MAP2 showed
neuronal localization as shown for RARc present in both
the nucleus and cytoplasm implying possibly both genomic
and non-genomic function (Fig. 2h) (as discussed below).
qPCR analysis of RALDHs and RARs was performed
on samples of caudal hippocampus from three subjects to
determine the expression of their respective mRNA tran-
scripts. The RALDHs were identiﬁed within 23 cycles
indicating substantial levels of all three enzymes with
Fig. 2 Elements of the RA synthesis and signalling pathway in the
human dentate gyrus. A sensitive immunoﬂuorescence technique used
for human hippocampal sections showed differing distributions of the
RALDH proteins in the dentate gyrus (DG, a–c). All three proteins
were present in a proportion of cells with extensive labelling
for RALDH2 (b) and RALDH3 (c) with less labelling seen for
RALDH1 (a). An example of immunoﬂuorescence double labelling
for RALDH1 with the neuronal marker MAP2 showed predominantly
cytoplasmic (shown by arrow) but also some nuclear localization in
neurons (d), the inset shows the separate colour channels for the main
merged image. Immunoﬂuorescence was used to detect the presence
of RARa, b and c in the human hippocampus. Positive staining was
seen for all three receptors (e–g) in the dentate gyrus. Greatest
staining was observed for RARb (f) followed by RARa (e) and RARc
(g). Using immunoﬂuorescence double labelling with MAP2, RARc
is shown to have a nuclear localization (shown by arrow)( h), the
inset shows the separate colour channels for the main merged image.
Quantitative real-time PCR showed that all RALDH genes were
expressed in the hippocampus (i) and RALDH2 was particularly
prominent. Similarly, all three RARs transcripts were present in
the hippocampus (j) in particular RARb. All expression levels are
shown relative to the expression of the housekeeping gene b-actin.
SEM are shown for an n = 3. Scale bars a–c and e–g 40 lm, d and
h 40 lm
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qPCR analysis of transcript expression by qPCR found
RARa, b and c were expressed in the hippocampus with
RARb being the most prominent (Fig. 2j).
Expression of retinoic acid synthetic enzymes
and receptors in neurons of the human hippocampal
CA1 subﬁeld
RALDH1, 2 and 3 were also present in neurons of the
cornu ammonis (CA) subﬁelds of the hippocampus as
determined by double-labelling with MAP2 (Fig. 3a–c)
and compared with a negative control lacking RALDH
primary antibody (Fig. 3d). The enzymes were predomi-
nantly localised to the cytoplasm and were also present in
some cell processes, while some cells also showed nuclear
localization as has been recently shown in rodent astrocytes
(Wang et al. 2011).
Nuclear RARs regulate gene expression in a ligand-
activated fashion (Chambon 1996) while more recently
cytoplasmic RARs have been demonstrated to perform non-
genomic roles, regulating various kinases (Rochette-Egly
and Germain 2009) as well as protein translation (Chen
et al. 2008; Poon and Chen 2008). Each RAR showed a
distinctive subcellular distribution (Fig. 4a–c) compared
with the negative control without RAR primary antibody
(Fig. 4d). RARa was present in the nucleus as well as
showing a perinuclear distribution (Fig. 4a), RARb was
identiﬁed in the cell nucleus and cytoplasm (Fig. 4b) and
RARc was found predominantly in the nucleus (Fig. 4c).
No RAR staining was observed in the cell processes,
contrasting with in vitro cultured neurons that can show
strong expression within neuronal processes (unpublished
observation).
Relative number of neurons in the dentate gyrus
and CA1 expressing retinoic acid synthetic enzymes
and receptors
Numbers of MAP2 positive neurons in the dentate gyrus
and CA1 subﬁelds expressing either RALDHs or the RARs
were counted to determine the relative distribution of these
components of the RA-signalling pathway. RALDH1 was
signiﬁcantly less expressed in the dentate gyrus (56%),
than RALDH2 (84%, P\0.001) or RALDH3 (77%,
P\0.01) (Fig. 5a, b). A signiﬁcantly smaller proportion
of neurons in CA1 expressed these enzymes compared with
the dentate gyrus (Fig. 5a). Similarly, the RA receptors
Fig. 3 RALDH1, 2 and 3 are present in neuronal cells of the human
CA1 hippocampal subﬁeld. Double labelling immunoﬂuorescence
with the neuronal marker MAP2 showed RALDH1 (a), RALDH2
(b) and RALDH3 (c) proteins present in neurons of CA1. Each image
panel shows the separate colour channels as smaller inserts to the left
of the main merged image. The distribution of these proteins is
predominantly cytoplasmic but with some expression in the nucleus
(as shown by arrows in a–c). A negative control sample that was
stained with MAP2 but no RALDH antibody showed absence of
background staining (d). All scale bars 20 lm
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neurons in the CA1 subﬁeld compared with the dentate
gyrus (P\0.001) (Fig. 5b).
Discussion
This study shows the strong expression in the human hip-
pocampus of the components required for RA signalling;
both the enzymes necessary for RA synthesis as well as the
receptors required to respond to the signal. This is the ﬁrst
report to describe the RA synthetic enzymes in the human
brain, ﬁnding varying levels of the three subtypes,
RALDH1, 2 and 3, in hippocampal neurons. Given that the
RALDH expression correlates very well with localised
regions of RA synthesis (Niederreither et al. 1997; Swin-
dell et al. 1999; Wagner et al. 2002) and mutation of
RALDHs completely eliminate RA synthesis [as reviewed
(Duester 2008)] this implies these neurons are capable of
generating RA. This contrasted to the complete lack of
these enzymes in mouse hippocampal neurons, the proba-
ble source of RA being the nearby meninges (Sakai et al.
2004). Of the receptors, RARa, b and c could be detected
in neurons in the dentate gyrus while a smaller proportion
of neurons within CA1 expressed these receptors. This
contrasts with mouse in which RARc is the only receptor
present in the dentate gyrus while in the CA1/CA3 sub-
ﬁelds RARa and c are expressed as described by Krezel
et al. (1999). They describe the importance of examining
RA receptor protein expression, as opposed to transcript,
because of the surprisingly large discrepancies in certain
regions of the brain presumably indicating extensive post-
transcriptional regulation of the RA receptors (Krezel et al.
1999). Very few papers have described RA receptors in the
human brain, although Rioux and Arnold reported RARa
and RARc in only approximately 12% of granule neurons
and RARa in some neurons of the hippocampal subﬁelds
(Rioux and Arnold 2005). However, this paper used
immunohistochemistry in the absence of antigen retrieval
which is likely to provide only low sensitivity of detection
in contrast to the high sensitivity of the immunoﬂuorescent
technique employed in this study, comparable to the
methods used in rodent model species. The high expression
of both receptors and RA synthetic enzymes compared
with mouse models implies a crucial function in the human
hippocampus. One recently discovered potential function
for RA in the hippocampus is regulation of synaptic
scaling.
Fig. 4 Subcellular distribution of RARa, RARb and RARc in human
CA1 neurons. RARs were shown to co-localise with neurons as
determined by MAP2 double-labelling (a–c). Each image panel
shows the separate colour channels as smaller inserts to the left of the
main merged image. RARa protein was observed in the nucleus and
the perinuclear region (as shown by arrows, a), RARb was observed
both in the nucleus and the surrounding cytoplasm of neurons (as
shown by arrow, b) and RARc was detected in neuronal nuclei (as
shown by arrows, c). A negative control sample that was stained with
MAP2 but no RAR antibody was run alongside the positive samples
(d). All scale bars 20 lm
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123Synaptic scaling is one mechanism providing balance to
neuronal ﬁring rates, maintaining homeostasis within
neuronal networks (Turrigiano 2008). The regulatory sys-
tem includes transient synthesis and insertion of AMPA
receptors at synapses (Ju et al. 2004; Sutton et al. 2006).
Regulated RA synthesis in neurons has been proposed as a
mechanism to control this process; when the action
potential of cultured neurons is blocked with tetrodotoxin
together with a block of NMDA receptors with amino-
phosphonovalerate this induces synaptic scaling (Ju et al.
2004; Sutton et al. 2006) proposed to be mediated by a
local increase in RA synthesis promoting local translation
of AMPA receptor (Aoto et al. 2008). In contrast to the
majority of RA’s actions through transcriptional regulation
via RA receptors in the nucleus, this is a non-genomic
mechanism in which RARa directly interacts with speciﬁc
mRNAs to inhibit translation, this inhibition being released
on binding to RA (Poon and Chen 2008) in a process that
also involves the fragile X protein FMRP (Soden and Chen
2010). Interestingly, in the human hippocampus it is RARb
detected in the cytoplasm, while RARa and c tend to be
restricted to the nucleus; thus RARb may be more crucial
for such non-genomic functions. It is proposed that
RALDH1 catalyses RA synthesis for synaptic scaling and
high levels of RALDH1 are reported in cultured mouse
hippocampal neurons (Aoto et al. 2008). However, this
new study and those of others (Wagner et al. 2002) show
that none of the RALDHs are strongly expressed in
endogenous rodent hippocampal neurons, and these plastic
processes must rely on only low levels of RA. We now
show, however, that human neurons in situ show strong
RALDH expression and synaptic scaling may thus be
mediated by endogenous RA in the human hippocampus.
Controversy has developed over the effect of RA on the
human brain because of the use of the 13-cis isomer of RA
as the active agent in the acne drug isotretinoin. Although it
is clear that there are a number of adverse effects in the
CNS, the most common being headache (Bremner and
McCaffery 2008), many studies have linked the onset of
depression with such treatment (Hazen et al. 1983; Gatti
and Serri 1991; Jick et al. 2000; Bremner et al. 2005;
Azoulay et al. 2008) while other studies have found the
contrary (Rubinow et al. 1987; Ng et al. 2002; Cohen et al.
2007; Bozdag et al. 2009; McGrath et al. 2010). One
profound problem in resolving this quandary is the difﬁ-
culty in untangling the psychosocial inﬂuence of severe
acne with the potential effects of the drug. Understanding
the biological effects of RA on the brain is thus crucial.
Rodent animal studies have shown the requirement of
retinoids on functions as diverse as learning and memory
performance (Etchamendy et al. 2001), sleep (Maret et al.
2005) and mesolimbic system-driven locomotion (Krezel
et al. 1998); deﬁcits in all these systems result from a
reduction in RA signalling. Not just deﬁciency but excess
RA also disrupts RA signalling and treatment of mice with
RA at the same dose used for acne treatment alters hip-
pocampal neurogenesis, leading to decreased numbers of
newborn neurons together with a reduced performance in
the radial maze test (Crandall et al. 2004). Similarly,
treatment of rats with RA also leads to degradation in
performance in learning and memory tests (Dopheide and
Morgan 2008) while others have reported an increase in
anxiety like behaviour (Cai et al. 2010). Despite these
multiple effects by RA on the CNS, its inﬂuence on
Fig. 5 Quantiﬁcation of neuronal RALDH and RAR expression.
Neurons double labelled for MAP2 and RALDH1–3 or MAP2 and
RARa–c were quantiﬁed in the dentate gyrus and CA1 sub-regions of
the human hippocampus. A comparison of the number of RALDH
positive neurons in the dentate gyrus showed that RALDH1 was
signiﬁcantly less expressed than RALDH2 and RALDH3 in MAP2-
positive cells (a). When RALDH positive cells were compared
between the hippocampal sub-ﬁelds there were signiﬁcantly more
stained neurons in the dentate gyrus than in CA1. Evaluation of RAR-
positive neurons showed no differences within sub-ﬁelds but a
signiﬁcant difference between areas, with CA1 containing less RAR-
positive MAP2 cells than the dentate gyrus (b). **P\0.01 and
***P\0.001
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123depression-like behaviour in the rodent is less clear with
several studies pointing to an increase in some depressive-
like behaviours (O’Reilly et al. 2006; Trent et al. 2009)
with others studies showing no change (Ferguson et al.
2005, 2007). One possible explanation for variation in
result between studies is the baseline of RA signalling—
RA exhibits a U-shaped curve in its toxicity, with detri-
mental effects in both deﬁciency and excess and endoge-
nous levels crucially inﬂuence the possible harmful effect
of an exogenous dose. The high levels of RA-synthesizing
enzymes in the human hippocampus likely results in a very
different response of the CNS to drugs such as isotretinoin
compared with rodent models, where the expression of
these enzymes is much lower. This needs to be taken into
account when it comes to interpretation of these models but
almost certainly means that the human CNS will have an
altered sensitivity to RA. Further, the likelihood of high
levels of RA synthesis in the human hippocampus will
have consequences for the reliance of the brain on vitamin
A. It is known that vitamin A levels in the brain can decline
with age (Craft et al. 2004) while the carotenoid form
of vitamin A is protective against cognitive decline
(Grodstein et al. 2007) and retinoic acid has been reported
to provide protection from Alzheimer’s disease (Corcoran
et al. 2004; Ono et al. 2004; Husson et al. 2006; Brouillette
and Quirion 2007; Donmez et al. 2010; Shudo et al. 2009).
The human hippocampus may have a lower resilience to a
decline in vitamin A than rodent model species.
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